Covering all aspects of the pharma industry and across all therapeutic areas, Kevin has interviewed pretty much all the leading figures in the sector. A regular attendee at financial and medical conferences (and moderating at some), he has also appeared on BBC television and radio, ITV and Channel 4 to discuss the industry. Fluent in Spanish, he previously worked as a journalist on rock/pop music publications, was chief sub editor at Catholic newspaper The Universe and contributed articles to the likes of The Independent and the Manchester Evening News on football.
Latest from Kevin Grogan
The Spanish company's Lilly-partnered atopic dermatitis drug is enjoying a decent launch in Germany and in other European countries, "we are getting the price that we wanted," claims CEO Carlos Gallardo.
Medixci’s Nick Williams told attendees at BIO-Europe that it was a shame that promising biotechs head to the NASDAQ as soon as possible. He and called for a change in culture from investors and for them to back the continent’s start-ups with proper funding.
The Denmark-based major intends to build on its heritage in diabetes and is keen to hear from innovators in a space where prevalence is on the rise but is not being served by improved new products.
The company, now the most advanced clinically in the psychedelic space after the rejection of Lykos's MDMA-based post-traumatic stress disorder drug, is cutting its workforce by a third and narrowing its research focus after shifting the timeline for its late-stage depression candidate.
As it posts third-quarter numbers that again reveal the decline of revenues from its multiple sclerosis portfolio, the US biotech major is entering into the hot area of targeted protein degradation to boost its immunology and neurology pipeline.
The Swiss giant has raised its forecast for the full financial year, as Cosentyx, Entresto and its oncology portfolio continue to shine, helped by the firm's sleeker selling organization.